<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939820</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTR02-007</org_study_id>
    <nct_id>NCT02939820</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)</brief_title>
  <official_title>Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide expanded access of patisiran to patients with&#xD;
      hereditary transthyretin-mediated amyloidosis (hATTR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choosing to participate in an expanded access program is an important personal decision. Talk&#xD;
      with your doctor and family members or friends about deciding to join a research study. To&#xD;
      learn more about this study, please have your doctor contact the study research staff using&#xD;
      the Contacts provided. For general information, see the links provided in More Information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>TTR-mediated Amyloidosis</condition>
  <condition>Amyloidosis, Hereditary</condition>
  <condition>Amyloid Neuropathies, Familial</condition>
  <condition>Familial Amyloid Polyneuropathies</condition>
  <condition>Amyloid Neuropathies</condition>
  <condition>Amyloidosis, Hereditary, Transthyretin-Related</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patisiran (ALN-TTR02)</intervention_name>
    <description>patisiran (ALN-TTR02) administered by intravenous (IV) infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female greater than or equal to 18 years of age&#xD;
&#xD;
          -  Have a diagnosis of hATTR&#xD;
&#xD;
          -  Meet Karnofsky performance status and Polyneuropathy Disability (PND) score&#xD;
             requirements&#xD;
&#xD;
          -  Have adequate complete blood counts, liver function tests and coagulation tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participated in an interventional hATTR amyloidosis clinical trial involving RNA&#xD;
             interference (RNAi) therapeutics within the last 12 months&#xD;
&#xD;
          -  Are currently eligible to participate in or currently enrolled in an ongoing&#xD;
             interventional hATTR amyloidosis clinical trial&#xD;
&#xD;
          -  Have inadequate cardiac function&#xD;
&#xD;
          -  Known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis&#xD;
&#xD;
          -  Have known serious comorbidities or considered unfit for the program by the&#xD;
             investigator&#xD;
&#xD;
          -  Prior or planned liver or heart transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/transthyretin-amyloidosis</url>
    <description>https://ghr.nlm.nih.gov/condition/transthyretin-amyloidosis</description>
  </link>
  <link>
    <url>https://www.nlm.nih.gov/medlineplus/amyloidosis.html</url>
    <description>https://www.nlm.nih.gov/medlineplus/amyloidosis.html</description>
  </link>
  <link>
    <url>https://rarediseases.info.nih.gov/gard/8708/amyloid-neuropathy/resources/1</url>
    <description>https://rarediseases.info.nih.gov/gard/8708/amyloid-neuropathy/resources/1</description>
  </link>
  <link>
    <url>https://rarediseases.info.nih.gov/gard/656/familial-transthyretin-amyloidosis/resources/1</url>
    <description>https://rarediseases.info.nih.gov/gard/656/familial-transthyretin-amyloidosis/resources/1</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>FAP</keyword>
  <keyword>Familial Amyloid Polyneuropathies</keyword>
  <keyword>TTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloidosis, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

